Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: A case series

Maria Morritti, Giuseppe Iodice, Assunta Melaccio, Loretta D'Onofrio, Paola Bergnolo, Antonella Boglione, Alessandro Comandone, Peppina Molinaro, Danula Garigliano

Research output: Contribution to journalArticle

Abstract

During the last decades, much effort has been made to develop and test treatments for advanced/metastatic breast cancer (MBC) able to prolong survival and improve patients' quality of life. In this regard, eribulin represents one of the most recent and interesting discoveries. This tubulin-targeting chemotherapy demonstrated a survival benefit in MBC women who progressed after at least two prior lines of chemotherapy for the treatment of metastatic disease (prior therapies should have included an anthracycline and a taxane, in either adjuvant or metastatic setting). Here, we described five cases of heavily pretreated MBC patients who experienced long-lasting control of disease with eribulin.

Original languageEnglish
Pages (from-to)25-33
Number of pages9
JournalFuture Oncology
Volume13
Issue number11s
DOIs
Publication statusPublished - May 1 2017

Keywords

  • chemotherapy
  • eribulin
  • line of treatment
  • metastatic breast cancer
  • progression-free survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: A case series'. Together they form a unique fingerprint.

  • Cite this

    Morritti, M., Iodice, G., Melaccio, A., D'Onofrio, L., Bergnolo, P., Boglione, A., Comandone, A., Molinaro, P., & Garigliano, D. (2017). Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: A case series. Future Oncology, 13(11s), 25-33. https://doi.org/10.2217/fon-2016-0529